CD19 and hematologic disorder: Notably, a phase I/II clinical trial for treating relapsed or refractory CD19-positive hematologic malignancy using CB-derived CAR NK cells, and seven out of eleven patients showed complete remission, with no significant CRS or ICANS (NCT03056339) [180].